



Medicine Use in Upper Respiratory Airways and Asthma

Guest Editors:

Dr. Sinthia Bosnic-Anticevich

Sydney Pharmacy School,
Faculty of Medicine and Health,
University of Sydney, Sydney,
NSW 2006, Australia

Dr. Vicky Kritikos

Woolcock Institute of Medical
Research, University of Sydney,
Sydney, Australia

Dr. Biljana Cvetkovski

Woolcock Institute of Medical
Research, University of Sydney,
Sydney, Australia

Message from the Guest Editors

Chronic, allergic, airway diseases, specifically asthma and rhinitis, are on the rise worldwide, and represent an enormous health and economic burden to individuals, healthcare systems, and society. When it comes to the management of these conditions, which often coexist, the inappropriate use of medications is a major issue and remains a persistent barrier to achieving optimal patient outcomes. This has been highlighted by the recent Lancet Asthma Commission, calling for effective methods of identifying and addressing non-adherence to inhaled preventative asthma medication, and Allergic Rhinitis and its Impact on Asthma (ARIA) in Pharmacy, identifying the need for delivery of strategies and interventions that address suboptimal rhinitis and asthma control arising from suboptimal treatment.

Deadline for manuscript
submissions:

closed (31 May 2020)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Jon Schommer

College of Pharmacy, University
of Minnesota, Minneapolis, MN
55455, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Pharmacy* (ISSN 2226-4787). *Pharmacy*, an international scientific open access journal on pharmacy education and practice, is published by MDPI online quarterly. *Pharmacy* is published in open access format—research articles, reviews and other contents are released on the Internet immediately after acceptance.

The scientific community and the general public have unlimited and free access to the content as soon as it is published.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [ESCI \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), and [other databases](#).

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 24.6 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2023).

Contact Us

Pharmacy
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmacy
pharmacy@mdpi.com
[@Pharmacy_MDPI](https://twitter.com/Pharmacy_MDPI)